Keyphrases
Pediatric
100%
Hematopoietic Cell Transplantation
100%
Alemtuzumab
100%
Severe Aplastic Anemia
100%
Reduced Intensity Transplantation
100%
Unrelated Donor Transplantation
75%
Immune Reconstitution
50%
Immune Suppression
50%
Graft-versus-host Disease (GvHD)
25%
Multicenter Trial
25%
Immunosuppression
25%
Overall Survival
25%
Immunosuppressive Therapy
25%
Infection Rate
25%
5-year Survival
25%
High Failure Rate
25%
First Year
25%
Median Time
25%
Graft Rejection
25%
Treatment-related Mortality
25%
Blood Cancer
25%
Event-free Survival
25%
Laboratory Measures
25%
Neutrophil Engraftment
25%
Donor Engraftment
25%
HLA-matched Donor
25%
Unrelated Donor
25%
Reduced-intensity Conditioning
25%
Fludarabine
25%
Melphalan
25%
Good Quality of Life
25%
Platelet Engraftment
25%
Biochemistry, Genetics and Molecular Biology
Cell Transplantation
100%
Alemtuzumab
100%
Hematopoietic Cell
100%
Immune Reconstitution
50%
Overall Survival
50%
Conditioning
50%
Infection Rate
25%
Event Free Survival
25%
Melphalan
25%
Fludarabine
25%
Platelet
25%
Pharmacology, Toxicology and Pharmaceutical Science
Aplastic Anemia
100%
Alemtuzumab
100%
Overall Survival
50%
Malignant Neoplasm
25%
Infection Rate
25%
Melphalan
25%
Immunosuppressive Agent
25%
Acute Graft Versus Host Disease
25%
Event Free Survival
25%
Graft Rejection
25%
Fludarabine
25%
Hexachlorophene
25%